JP6158833B2 - ベータ−カテニン関連疾患を処置するための有機組成物 - Google Patents

ベータ−カテニン関連疾患を処置するための有機組成物 Download PDF

Info

Publication number
JP6158833B2
JP6158833B2 JP2014551706A JP2014551706A JP6158833B2 JP 6158833 B2 JP6158833 B2 JP 6158833B2 JP 2014551706 A JP2014551706 A JP 2014551706A JP 2014551706 A JP2014551706 A JP 2014551706A JP 6158833 B2 JP6158833 B2 JP 6158833B2
Authority
JP
Japan
Prior art keywords
strand
beta
catenin
rnai agent
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014551706A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015503608A (ja
JP2015503608A5 (cg-RX-API-DMAC7.html
Inventor
ヒュースケン，ディーター
ベテンコート，ブライアン
バムクロット，デイビッド
クチマンチ，サティアナラヤナ
ミルステイン，スチュアート
ジェーアール．，マイケル シラバク
ジェーアール．，マイケル シラバク
ピー． ステグマイアー，フランク
ピー． ステグマイアー，フランク
ワームス，マーカス
ウェイラー，ジャン
Original Assignee
アローヘッド ファーマシューティカルズ インコーポレイテッド
アローヘッド ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アローヘッド ファーマシューティカルズ インコーポレイテッド, アローヘッド ファーマシューティカルズ インコーポレイテッド filed Critical アローヘッド ファーマシューティカルズ インコーポレイテッド
Publication of JP2015503608A publication Critical patent/JP2015503608A/ja
Publication of JP2015503608A5 publication Critical patent/JP2015503608A5/ja
Application granted granted Critical
Publication of JP6158833B2 publication Critical patent/JP6158833B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2014551706A 2012-01-09 2013-01-08 ベータ−カテニン関連疾患を処置するための有機組成物 Active JP6158833B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261584530P 2012-01-09 2012-01-09
US61/584,530 2012-01-09
US201261598530P 2012-02-14 2012-02-14
US61/598,530 2012-02-14
PCT/IB2013/050159 WO2013105022A2 (en) 2012-01-09 2013-01-08 Organic compositions to treat beta-catenin-related diseases

Publications (3)

Publication Number Publication Date
JP2015503608A JP2015503608A (ja) 2015-02-02
JP2015503608A5 JP2015503608A5 (cg-RX-API-DMAC7.html) 2016-03-03
JP6158833B2 true JP6158833B2 (ja) 2017-07-05

Family

ID=47720548

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014551706A Active JP6158833B2 (ja) 2012-01-09 2013-01-08 ベータ−カテニン関連疾患を処置するための有機組成物

Country Status (9)

Country Link
US (3) US10023862B2 (cg-RX-API-DMAC7.html)
EP (1) EP2802658A2 (cg-RX-API-DMAC7.html)
JP (1) JP6158833B2 (cg-RX-API-DMAC7.html)
CN (1) CN104302768A (cg-RX-API-DMAC7.html)
AU (1) AU2013208720A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014016870A2 (cg-RX-API-DMAC7.html)
CA (1) CA2860676A1 (cg-RX-API-DMAC7.html)
HK (1) HK1205758A1 (cg-RX-API-DMAC7.html)
WO (1) WO2013105022A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3134527B1 (en) * 2014-04-22 2018-12-12 Medizinische Hochschule Hannover Lncrnas for therapy and diagnosis of angiogenesis
WO2017160983A1 (en) 2016-03-16 2017-09-21 Dicerna Pharmaceuticals, Inc. Compositions and methods for the treatment of a beta-catenin-associated disease or disorder
US11185553B2 (en) * 2016-10-31 2021-11-30 Samsung Life Public Welfare Foundation Pharmaceutical composition for preventing or treating ischemic-reperfusion injury comprising bile acids
AU2019205904A1 (en) 2018-01-05 2020-06-18 Dicerna Pharmaceuticals, Inc. Reducing beta-catenin and IDO expression to potentiate immunotherapy
WO2019161105A1 (en) * 2018-02-14 2019-08-22 Deep Genomics Incorporated Oligonucleotide therapy for wilson disease
CN111500694B (zh) * 2019-01-31 2023-02-24 中国科学院脑科学与智能技术卓越创新中心 Baz2b基因作为靶点在缓解衰老中的应用
TW202130809A (zh) * 2019-10-29 2021-08-16 美商愛羅海德製藥公司 用於抑制β-ENaC表現之RNAi藥劑、其組合物及使用方法
WO2022125725A1 (en) 2020-12-09 2022-06-16 The Regents Of The University Of Michigan Compositions and methods for treating wnt-driven cancer
JP2024508333A (ja) * 2021-03-01 2024-02-26 ステッドマン・フィリポン・リサーチ・インスティテュート カテニンｍＲＮＡを含む組成物および骨折を治すためのその使用
WO2023003995A1 (en) * 2021-07-23 2023-01-26 Alnylam Pharmaceuticals, Inc. Beta-catenin (ctnnb1) irna compositions and methods of use thereof
WO2025090541A1 (en) * 2023-10-25 2025-05-01 The Regents Of The University Of California Covalent degraders of oncogenic transcription factors

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696561B1 (en) 1909-07-09 2004-02-24 Basf Aktiengesellschaft Corynebacterium glutamicum genes encoding proteins involved in membrane synthesis and membrane transport
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US5030453A (en) 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5266573A (en) 1989-08-07 1993-11-30 Elf Sanofi Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US5891467A (en) 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2323726C (en) 1998-03-20 2005-02-08 Benitec Australia Ltd. Control of gene expression
EP1143957A3 (en) 1998-12-16 2002-02-27 Warner-Lambert Company Treatment of arthritis with mek inhibitors
EP2314700A1 (en) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
IL145778A0 (en) 1999-04-21 2002-07-25 American Home Prod Methods and compositions for inhibiting the function of polynucleotide sequences
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
BR0012325A (pt) 1999-07-09 2002-05-21 American Home Prod Métodos e composições para prevenção da formação de rna anormal durante a transcrição de uma sequência de plasmìdeo
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
RU2164944C1 (ru) 1999-12-09 2001-04-10 Институт молекулярной биологии им. В.А. Энгельгардта РАН Способ изменения генетических свойств организма
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
IL151781A0 (en) 2000-03-16 2003-04-10 Genetica Inc Methods and compositions for rna interference
AU2001240375A1 (en) 2000-03-17 2001-10-03 Benitec Australia Limited Genetic silencing
AU2001260140A1 (en) 2000-03-22 2001-10-03 Avntis Pharma Deutschland Gmbh Nematodes as model organisms for the investigation of neurodegenerative diseases, in particular parkinsons disease, uses and methods for the discovery of substances and genes which can be used in the treatment of the above disease states and identification of a nematode gene.
DE60140676D1 (de) 2000-03-30 2010-01-14 Massachusetts Inst Technology Mediatoren von rns-interferenz, die rns-sequenzspezifisch sind
WO2001092513A1 (en) 2000-05-30 2001-12-06 Johnson & Johnson Research Pty Limited METHODS FOR MEDIATING GENE SUPPRESION BY USING FACTORS THAT ENHANCE RNAi
US6680068B2 (en) 2000-07-06 2004-01-20 The General Hospital Corporation Drug delivery formulations and targeting
JP3811775B2 (ja) 2000-07-19 2006-08-23 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー ４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル
US20030166064A1 (en) 2000-08-03 2003-09-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
CZ308053B6 (cs) 2000-12-01 2019-11-27 Max Planck Gesellschaft Izolovaná molekula dvouřetězcové RNA, způsob její výroby a její použití
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
WO2002100435A1 (en) 2001-06-11 2002-12-19 Centre Hospitalier Universitaire De Montreal Compositions and methods for enhancing nucleic acid transfer into cells
ATE468861T1 (de) 2001-08-16 2010-06-15 Univ Pennsylvania Synthese und verwendung von reagenzien für die verbesserte dna-lipofektion und/oder prodrug- und arzneimitteltherapien mit langsamer freisetzung
DE10230997A1 (de) 2001-10-26 2003-07-17 Ribopharma Ag Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
ATE529512T1 (de) 2002-02-01 2011-11-15 Life Technologies Corp Doppelsträngige oligonukleotide
DE60321141D1 (en) 2002-03-05 2008-07-03 Axys Pharm Inc Cathepsin-cystein-protease-hemmer
MXPA04008722A (es) 2002-03-08 2005-07-13 Eisai Co Ltd Compuestos macrociclicos utiles como farmaceuticos.
UA77765C2 (en) 2002-03-13 2007-01-15 Array Biopharma Inc N3 alkylated derivatives of benzimidazole as mek inhibitors
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
ES2354607T3 (es) 2002-06-28 2011-03-16 Protiva Biotherapeutics Inc. Procedimiento y aparato para producir liposomas.
CA2500468A1 (en) 2002-09-28 2004-04-08 Massachussets Institute Of Technology Influenza therapeutic
US8090542B2 (en) 2002-11-14 2012-01-03 Dharmacon Inc. Functional and hyperfunctional siRNA
EP1585756B1 (en) 2002-11-26 2010-04-21 University of Massachusetts Delivery of sirnas
US7217807B2 (en) 2002-11-26 2007-05-15 Rosetta Genomics Ltd Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
US20040208921A1 (en) 2003-01-14 2004-10-21 Ho Rodney J. Y. Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
ATE479752T1 (de) * 2003-03-07 2010-09-15 Alnylam Pharmaceuticals Inc Therapeutische zusammensetzungen
WO2004091515A2 (en) 2003-04-09 2004-10-28 Alnylam Pharmaceuticals, Inc. iRNA CONJUGATES
JP4912873B2 (ja) * 2003-04-09 2012-04-11 アルナイラム ファーマシューティカルズ， インコーポレイテッド ｉＲＮＡ複合体
JP4951338B2 (ja) 2003-07-16 2012-06-13 プロチバ バイオセラピューティクス インコーポレイティッド 脂質に封入された干渉ｒｎａ
WO2005021749A1 (en) 2003-08-28 2005-03-10 Novartis Ag Interfering rna duplex having blunt-ends and 3’-modifications
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
CN101052717A (zh) 2004-05-11 2007-10-10 α基因株式会社 诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
KR101225018B1 (ko) 2004-09-02 2013-01-23 쿠리스 인코퍼레이션 헤지호그 신호전달에 대한 피리딜 억제제
WO2006031977A2 (en) * 2004-09-13 2006-03-23 The Regents Of The University Of California Inhibition of pancreatic cancer cell growth
CA2596845C (en) 2005-02-10 2016-11-08 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of diagnosing and treating cancer using b-catenin splice variants
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CA2618218C (en) 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
CA2628300C (en) 2005-11-02 2018-04-17 Protiva Biotherapeutics, Inc. Modified sirna molecules and uses thereof
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
WO2008109369A2 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
US20100105134A1 (en) 2007-03-02 2010-04-29 Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
KR20100024399A (ko) 2007-05-01 2010-03-05 엔즌 파마슈티칼스, 인코포레이티드 베타-카테닌의 조절용 ｒｎａ 길항제 화합물
NZ580712A (en) 2007-05-22 2011-12-22 Marina Biotech Inc Hydroxymethyl substituted rna oligonucleotides and rna complexes containing acyclic monomers
EP2173875B1 (en) 2007-06-15 2017-08-30 Cequent Pharmaceuticals, Inc. Bacteria mediated gene silencing
JP5658565B2 (ja) 2007-09-12 2015-01-28 ジェネンテック， インコーポレイテッド ホスホイノシチド３−キナーゼ阻害剤化合物と化学療法剤との組合せ、および使用方法
CN101909631B (zh) 2007-10-25 2012-09-12 健泰科生物技术公司 制备噻吩并嘧啶化合物的方法
US20100267626A1 (en) * 2007-11-05 2010-10-21 Novartis Ag Methods and compositions for measuring wnt activation and for treating wnt-related cancers
EP2238251B1 (en) 2007-12-27 2015-02-11 Protiva Biotherapeutics Inc. Silencing of polo-like kinase expression using interfering rna
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
TWI455944B (zh) 2008-07-01 2014-10-11 Daiichi Sankyo Co Ltd 雙股多核苷酸
EP2266550A1 (en) * 2009-06-15 2010-12-29 Institut Curie Antagonists of ß-catenin for preventing and/or treating neurodegenerative disorders
CA2677068A1 (en) 2009-09-01 2011-03-01 Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
CA2776796C (en) 2009-10-16 2018-11-13 University Health Network Porphyrin nanovesicles
MX339050B (es) * 2009-12-18 2016-05-09 Novartis Ag Composiciones organicas para tratar las enfermedades relacionadas con hsf1.
EP2591105B1 (en) * 2010-07-06 2017-05-31 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna
AU2011285909B2 (en) * 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)

Also Published As

Publication number Publication date
JP2015503608A (ja) 2015-02-02
BR112014016870A2 (pt) 2017-06-27
EP2802658A2 (en) 2014-11-19
WO2013105022A2 (en) 2013-07-18
US20150291954A1 (en) 2015-10-15
US20180282728A1 (en) 2018-10-04
US20250270555A1 (en) 2025-08-28
US10023862B2 (en) 2018-07-17
CN104302768A (zh) 2015-01-21
CA2860676A1 (en) 2013-07-18
WO2013105022A3 (en) 2013-10-31
HK1205758A1 (en) 2015-12-24
AU2013208720A1 (en) 2014-07-24

Similar Documents

Publication Publication Date Title
US20250270555A1 (en) Organic compositions to treat beta-catenin-related diseases
US11091761B2 (en) Organic compositions to treat HSF1-related diseases
JP6577073B2 (ja) ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物
US11261444B2 (en) Organic compositions to treat EPAS1-related diseases
AU2017268399A1 (en) Mrna combination therapy for the treatment of cancer
KR20140057374A (ko) Hsf1-관련 질환을 치료하기 위한 유기 조성물
TW202227101A (zh) 用於調節血管收縮素原表現之化合物及方法
WO2022026648A1 (en) Inhibition of incexact1 to treat heart disease
CN119137272A (zh) 血管紧张素原调节组合物和其使用方法
CN120456911A (zh) 用于抑制补体组分C3(C3)表达的RNAi剂、其药物组合物及使用方法
CN121152878A (zh) 用于抑制补体因子B (CFB)表达的RNAi剂、其药物组合物和使用方法

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20151125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170508

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170606

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170608

R150 Certificate of patent or registration of utility model

Ref document number: 6158833

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250